Zealand Pharma AS 2023 AR2
The report highlights Zealand Pharma's achievements in 2023, celebrating its 25th anniversary with significant progress in its peptide therapeutics pipeline. Key milestones include the advancement of its differentiated obesity portfolio, notably survodutide entering Phase 3 trials, and regulatory submissions to the US FDA for rare disease assets dasiglucagon and glepaglutide. The company also strengthened its financial position through capital increases and a new finance agreement with the European Investment Bank. Additionally, Zealand Pharma advanced its double materiality assessment to prepare for the Corporate Sustainability Reporting Directive (CSRD).
Company: Zealand Pharma AS
Sector: Health Care
Country: Denmark
Year: 2023
Type: AR2
Pages: 162
Zealand Pharma AS
Annual Report
The report highlights Zealand Pharma's achievements in 2023, celebrating its 25th anniversary with significant progress in its peptide therapeutics pipeline. Key milestones include the advancement of its differentiated obesity portfolio, notably survodutide entering Phase 3 trials, and regulatory submissions to the US FDA for rare disease assets dasiglucagon and glepaglutide. The company also strengthened its financial position through capital increases and a new finance agreement with the European Investment Bank. Additionally, Zealand Pharma advanced its double materiality assessment to prepare for the Corporate Sustainability Reporting Directive (CSRD).
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees